Jefferies Raises Price Target On Amylin Pharmaceuticals (AMLN) to $30 After Q4 Results/Guidance
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 19
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 19
Join SI Premium – FREE
Jefferies boosted its estimates and price target on Buy-rated Amylin Pharmaceuticals (NASDAQ: AMLN) from $25 to $30 following Q4 results, with guidance that suggests upside to sales estimates.
The firm comments, "AMLN announced 4Q11 and issued 2012 guidance on its call. We calculate that AMLN’s 2012 operating income guidance suggests a range of $525-610m in combined Byetta/Bydureon U.S. sales in 2012, higher than our previous estimates. We continue to believe that the Street has underestimated the potential of the Byetta/Bydureon franchise."
The firm boosted FY12 EPS from ($1.91) to ($0.96), next year was cut from ($0.98) to ($1.21). For they current quarter (Q1) they see ($0.20).
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $16.68 yesterday.
The firm comments, "AMLN announced 4Q11 and issued 2012 guidance on its call. We calculate that AMLN’s 2012 operating income guidance suggests a range of $525-610m in combined Byetta/Bydureon U.S. sales in 2012, higher than our previous estimates. We continue to believe that the Street has underestimated the potential of the Byetta/Bydureon franchise."
The firm boosted FY12 EPS from ($1.91) to ($0.96), next year was cut from ($0.98) to ($1.21). For they current quarter (Q1) they see ($0.20).
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $16.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- Giant Biogene Holding Co (2367:HK) PT Raised to HK$46 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
